{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:46:06Z","timestamp":1787244366639,"version":"build-2736575974"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>ANCA-assoziierte Vaskulitiden (AAV) sind seltene, komplexe systemische Erkrankungen, die aufgrund unspezifischer klinischer Symptome zum Zeitpunkt der Konsultation oft schwer zu diagnostizieren sind. Der klinische Verlauf kann jedoch sehr schwerwiegend und sogar lebensbedrohlich sein und eine sofortige Diagnose und Behandlung erfordern.<\/jats:p>\n                  <jats:p>Daher ist es wichtig, die \u00c4rzteschaft f\u00fcr diese Erkrankung zu sensibilisieren und Kolleg*innen zu unterst\u00fctzen, die nicht regelm\u00e4\u00dfig mit diesen seltenen Krankheiten konfrontiert sind. Die \u00d6sterreichische Gesellschaft f\u00fcr Nephrologie (\u00d6GN) und die \u00d6sterreichische Gesellschaft f\u00fcr Rheumatologie (\u00d6GR) stellen hier einen gemeinsamen Konsens dar\u00fcber vor, wie Patient*innen mit Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA) am besten diagnostiziert und behandelt werden k\u00f6nnen.<\/jats:p>","DOI":"10.1007\/s00508-023-02262-9","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:01:56Z","timestamp":1695200516000},"page":"656-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnose und Therapie der Granulomatose mit Polyangiitis und mikroskopische Polyangiitis\u00a0\u2013 2023: Konsens-Empfehlungen der \u00d6sterreichischen Gesellschaften f\u00fcr Nephrologie (\u00d6GN) &amp; Rheumatologie (\u00d6GR)","Diagnosis and therapy of granulomatosis with polyangiitis and microscopic polyangiitis\u20142023: consensus of the Austrian society of nephrology (\u00d6GN) and Austrian society of rheumatology (\u00d6GR)"],"prefix":"10.1007","volume":"135","author":[{"given":"Balazs","family":"Odler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Lhotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmgard","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"\u00d6berseder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Duftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gauckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hintenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Zwerina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"12","key":"2262_CR1","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.40313","volume":"69","author":"A Berti","year":"2017","unstructured":"Berti\u00a0A, Cornec\u00a0D, Crowson\u00a0CS, et al. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a\u00a0twenty-year US population-based study. Arthritis Rheumatol. 2017;69(12):2338\u201350.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2262_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann\u00a0O, Berden\u00a0A, de Groot\u00a0K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2262_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/art.41557","volume":"73","author":"SH Sarica","year":"2021","unstructured":"Sarica\u00a0SH, Gallacher\u00a0PJ, Dhaun\u00a0N, et al. Multimorbidity in antineutrophil cytoplasmic antibody-associated Vasculitis: results from a\u00a0longitudinal, multicenter data linkage study. Arthritis Rheumatol. 2021;73(4):651\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2262_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/03009740802238366","volume":"37","author":"JH Takala","year":"2008","unstructured":"Takala\u00a0JH, Kautiainen\u00a0H, Malmberg\u00a0H, et\u00a0al. Wegener\u2019s granulomatosis in Finland in 1981\u20132000: clinical presentation and diagnostic delay. Scand J Rheumatol. 2008;37(6):435\u20138.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"2262_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.kint.2018.10.001","volume":"94","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler\u00a0A, Jayne\u00a0DRW. ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible? Kidney Int. 2018;94(6):1045\u20137.","journal-title":"Kidney Int"},{"issue":"8","key":"2262_CR6","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2215\/CJN.14561119","volume":"15","author":"EE Van Daalen","year":"2020","unstructured":"Van Daalen\u00a0EE, Wester Trejo\u00a0MAC, G\u00f6\u00e7ero\u011flu\u00a0A, et al. Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(8):1103\u201311.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2262_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","volume":"94","author":"SR Brix","year":"2018","unstructured":"Brix\u00a0SR, Noriega\u00a0M, Tennstedt\u00a0P, et al. Development and validation of a\u00a0renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177\u201388.","journal-title":"Kidney Int"},{"key":"2262_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102495","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler A, Shin JI, Lee KH, et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev. 2020. https:\/\/doi.org\/10.1016\/j.autrev.2020.102495.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2262_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/0394632015617063","volume":"29","author":"A Greco","year":"2016","unstructured":"Greco\u00a0A, Marinelli\u00a0C, Fusconi\u00a0M, et\u00a0al. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol. 2016;29(2):151\u20139.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"12","key":"2262_CR10","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1002\/art.30615","volume":"63","author":"PA Monach","year":"2011","unstructured":"Monach\u00a0PA, Tomasson\u00a0G, Specks\u00a0U, et al. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2011;63(12):3988\u201397.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2262_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/1529-0131(199707)40:7<1250::AID-ART9>3.0.CO;2-A","volume":"40","author":"OK Eberhard","year":"1997","unstructured":"Eberhard\u00a0OK, Haubitz\u00a0M, Brunkhorst\u00a0FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus\/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250\u20136.","journal-title":"Arthritis Rheum"},{"key":"2262_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1874312901409010071","volume":"9","author":"K Herrmann","year":"2015","unstructured":"Herrmann\u00a0K, Schinke\u00a0S, Csernok\u00a0E, et al. Diagnostic value of procalcitonin in ANCA-associated vasculitis (AAV) to differentiate between disease activity, infection and drug hypersensitivity. Open Rheumatol\u00a0J. 2015;9:71\u20136.","journal-title":"Open Rheumatol J"},{"issue":"3","key":"2262_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/03009742.2012.754939","volume":"42","author":"Z Hruskova","year":"2013","unstructured":"Hruskova\u00a0Z, Casian\u00a0AL, Konopasek\u00a0P, et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a\u00a0retrospective cohort study. Scand J Rheumatol. 2013;42(3):211\u20134.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"2262_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","volume":"92","author":"SP McAdoo","year":"2017","unstructured":"McAdoo\u00a0SP, Tanna\u00a0A, Hru\u0161kov\u00e1\u00a0Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693\u2013702.","journal-title":"Kidney Int"},{"issue":"2","key":"2262_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40620-017-0445-3","volume":"31","author":"M Crnogorac","year":"2018","unstructured":"Crnogorac\u00a0M, Horvatic\u00a0I, Kacinari\u00a0P, et\u00a0al. Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a\u00a0predictor of patient and renal outcome. J\u00a0Nephrol. 2018;31(2):257\u201362.","journal-title":"J Nephrol"},{"issue":"6","key":"2262_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman\u00a0GS, Kerr\u00a0GS, Leavitt\u00a0RY, et\u00a0al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488\u201398.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2262_CR17","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1183\/09031936.97.10122738","volume":"10","author":"A Schnabel","year":"1997","unstructured":"Schnabel\u00a0A, Holl-Ulrich\u00a0K, Dalhoff\u00a0K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir\u00a0J. 1997;10(12):2738\u201343.","journal-title":"Eur Respir J"},{"issue":"9","key":"2262_CR18","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ndt\/gfx248","volume":"32","author":"D Jayne","year":"2017","unstructured":"Jayne\u00a0D. Vasculitis\u2014when can biopsy be avoided? Nephrol Dial Transplant. 2017;32(9):1454\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"2262_CR19","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfab250","volume":"37","author":"MC Moura","year":"2022","unstructured":"Moura\u00a0MC, Fervenza\u00a0FC, Specks\u00a0U, et\u00a0al. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody associated vasculitis. Nephrol Dial Transplant. 2022;37(9):1710\u201321.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 103[1]","key":"2262_CR20","first-page":"111","volume":"35","author":"J Yoo","year":"2017","unstructured":"Yoo\u00a0J, Kim\u00a0HJ, Ahn\u00a0SS, et al. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis. Clin Exp Rheumatol. 2017;35(Suppl 103[1]):111\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2262_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11926-021-01002-0","volume":"23","author":"M Windpessl","year":"2021","unstructured":"Windpessl\u00a0M, Bettac\u00a0EL, Gauckler\u00a0P, et\u00a0al. ANCA status or clinical phenotype\u2014what counts more? Curr Rheumatol Rep. 2021;23(6):37.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"2262_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/art.41527","volume":"73","author":"L Delaval","year":"2021","unstructured":"Delaval\u00a0L, Samson\u00a0M, Schein\u00a0F, et al. Temporal arteritis revealing antineutrophil cytoplasmic antibody-associated vasculitides: Case-control study of 50 cases. Arthritis Rheumatol. 2021;73(2):286\u201394.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2262_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2013111233","volume":"26","author":"MJ Kemna","year":"2015","unstructured":"Kemna\u00a0MJ, Damoiseaux\u00a0J, Austen\u00a0J, et\u00a0al. ANCA as a\u00a0predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J\u00a0Am Soc Nephrol. 2015;26(3):537\u201342.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2262_CR24","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3899\/jrheum.141622","volume":"42","author":"M Yamaguchi","year":"2015","unstructured":"Yamaguchi\u00a0M, Ando\u00a0M, Kato\u00a0S, et al. Increase of antimyeloperoxidase antineutrophil cytoplasmic antibody (ANCA) in patients with renal ANCA-associated Vasculitis: association with risk to relapse. J\u00a0Rheumatol. 2015;42(10):1853\u201360.","journal-title":"J Rheumatol"},{"issue":"5","key":"2262_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","volume":"25","author":"ME McClure","year":"2019","unstructured":"McClure\u00a0ME, Wason\u00a0J, Gopaluni\u00a0S, et al. Evaluation of PR3-ANCA status after Rituximab for ANCA-associated Vasculitis. J\u00a0Clin Rheumatol. 2019;25(5):217\u201323.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"2262_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","volume":"19","author":"MD Morgan","year":"2017","unstructured":"Morgan\u00a0MD, Szeto\u00a0M, Walsh\u00a0M, et al. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a\u00a0reduced risk of relapse. Arthritis Res Ther. 2017;19(1):129.","journal-title":"Arthritis Res Ther"},{"key":"2262_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","author":"B Hellmich","year":"2023","unstructured":"Hellmich\u00a0B, Sanchez-Alamo\u00a0B, Schirmer\u00a0JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023; https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2262_CR28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K de Groot","year":"2009","unstructured":"de Groot\u00a0K, Harper\u00a0L, Jayne\u00a0DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2009;150(10):670\u201380.","journal-title":"Ann Intern Med"},{"issue":"4S","key":"2262_CR29","first-page":"S1","volume":"100","author":"KDIGO","year":"2021","unstructured":"KDIGO. 2021 clinical practice guideline for the management of Glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013S276.","journal-title":"Kidney Int"},{"issue":"3","key":"2262_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones\u00a0RB, Tervaert\u00a0JW, Hauser\u00a0T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N\u00a0Engl J Med. 2010;363(3):211\u201320.","journal-title":"N Engl J Med"},{"issue":"11","key":"2262_CR31","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/j.ekir.2021.08.009","volume":"6","author":"A Salas","year":"2021","unstructured":"Salas\u00a0A, Kant\u00a0S, Floyd\u00a0L, et al. ANCA vasculitis induction management during the COVID-19 pandemic. Kidney Int Rep. 2021;6(11):2903\u20137.","journal-title":"Kidney Int Rep"},{"issue":"21","key":"2262_CR32","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta\u00a0S, Nakagomi\u00a0D, Kobayashi\u00a0Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to Rituximab on remission induction in ANCA-associated vasculitis: a\u00a0randomized clinical trial. JAMA. 2021;325(21):2178\u201387.","journal-title":"JAMA"},{"issue":"7","key":"2262_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N\u00a0Engl J Med. 2021;384(7):599\u2013609.","journal-title":"N Engl J Med"},{"issue":"7","key":"2262_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated Vasculitis. N\u00a0Engl J Med. 2020;382(7):622\u201331.","journal-title":"N Engl J Med"},{"key":"2262_CR35","doi-asserted-by":"publisher","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","volume":"376","author":"M Walsh","year":"2022","unstructured":"Walsh\u00a0M, Collister\u00a0D, Zeng\u00a0L, et al. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ. 2022;376:e64604.","journal-title":"BMJ"},{"issue":"6","key":"2262_CR36","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","volume":"100","author":"K Gulati","year":"2021","unstructured":"Gulati\u00a0K, Edwards\u00a0H, Prendecki\u00a0M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021;100(6):1316\u201324.","journal-title":"Kidney Int"},{"issue":"2","key":"2262_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/kez001","volume":"58","author":"RJ Pepper","year":"2019","unstructured":"Pepper\u00a0RJ, McAdoo\u00a0SP, Moran\u00a0SM, et al. A\u00a0novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2019;58(2):373.","journal-title":"Rheumatology (Oxford)"},{"key":"2262_CR38","unstructured":"Fussner L, Flores-Suarez LF, Cartin-Ceba R, et al. Characteristics and outcomes of participants with and without diffuse alveolar hemorrhage in the plasma exchange and glucocorticoids in severe ANCA-associated Vasculitis (PEXIVAS) trial. Arthritis Rheumatol. 2022;74(suppl 9). https:\/\/acrabstracts.org\/abstract\/characteristics-and-outcomes-of-participants-with-and-without-diffuse-alveolar-hemorrhage-in-the-plasma-exchange-and-glucocorticoids-in-severe-anca-associated-vasculitis-pexivas-trial\/. Zugegriffen: 27.07.2023."},{"issue":"3","key":"2262_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone\u00a0JH, Merkel\u00a0PA, Spiera\u00a0R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"6","key":"2262_CR40","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","volume":"75","author":"S Unizony","year":"2016","unstructured":"Unizony\u00a0S, Villarreal\u00a0M, Miloslavsky\u00a0EM, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2262_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones\u00a0RB, Hiemstra\u00a0TF, Ballarin\u00a0J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a\u00a0randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399\u2013405.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2262_CR42","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","volume":"37","author":"A Berti","year":"2022","unstructured":"Berti\u00a0A, Alsawas\u00a0M, Jawaid\u00a0T, et al. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: A\u00a0systematic review and meta-analysis. Nephrol Dial Transplant. 2022;37(11):2190\u2013200.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2262_CR43","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot\u00a0K, Rasmussen\u00a0N, Bacon\u00a0PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461\u20139.","journal-title":"Arthritis Rheum"},{"issue":"26","key":"2262_CR44","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux\u00a0C, Mahr\u00a0A, Hamidou\u00a0MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N\u00a0Engl J Med. 2008;359(26):2790\u2013803.","journal-title":"N Engl J Med"},{"issue":"12","key":"2262_CR45","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/S2665-9913(21)00316-7","volume":"3","author":"SE Sattui","year":"2021","unstructured":"Sattui\u00a0SE, Conway\u00a0R, Putman\u00a0MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a\u00a0retrospective cohort study. Lancet Rheumatol. 2021;3(12):e855\u2013e64.","journal-title":"Lancet Rheumatol"},{"key":"2262_CR46","doi-asserted-by":"publisher","unstructured":"Kronbichler A, Geetha D, Smith RM, et al. The COVID-19 pandemic and ANCA-associated vasculitis\u2014reports from the EUVAS meeting and EUVAS education forum. Autoimmun Rev. 2021. https:\/\/doi.org\/10.1016\/j.autrev.2021.102986.","DOI":"10.1016\/j.autrev.2021.102986"},{"key":"2262_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac330","author":"D McGovern","year":"2022","unstructured":"McGovern\u00a0D, Jones\u00a0RB, Willcocks\u00a0LC, et al. Avacopan for ANCA-associated vasculitis\u2014information for prescribers. Nephrol Dial Transplant. 2022; https:\/\/doi.org\/10.1093\/ndt\/gfac330.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2262_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000506532","volume":"51","author":"AD Morris","year":"2020","unstructured":"Morris\u00a0AD, Elsayed\u00a0ME, Ponnusamy\u00a0A, et al. Treatment outcomes of anti-neutrophil cytoplasmic autoantibody-associated Vasculitis in patients over age 75 years: a\u00a0meta-analysis. Am J Nephrol. 2020;51(4):327\u201336.","journal-title":"Am J Nephrol"},{"issue":"4","key":"2262_CR49","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux\u00a0C, Qu\u00e9m\u00e9neur\u00a0T, Ninet\u00a0J, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a\u00a0multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67(4):1117\u201327.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2262_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1681\/ASN.V7133","volume":"7","author":"PH Nachman","year":"1996","unstructured":"Nachman\u00a0PH, Hogan\u00a0SL, Jennette\u00a0JC, et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J\u00a0Am Soc Nephrol. 1996;7(1):33\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2262_CR51","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/rheumatology\/keaa667","volume":"60","author":"P He","year":"2021","unstructured":"He\u00a0P, Hu\u00a0JP, Tian\u00a0XJ, et al. Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a\u00a0systematic review and meta-analysis of large observational studies. Rheumatology (Oxford). 2021;60(3):1067\u201379.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2262_CR52","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh\u00a0M, Flossmann\u00a0O, Berden\u00a0A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(2):542\u20138.","journal-title":"Arthritis Rheum"},{"issue":"19","key":"2262_CR53","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Karras\u00a0A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med. 2014;371(19):1771\u201380.","journal-title":"N Engl J Med"},{"issue":"9","key":"2262_CR54","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith\u00a0RM, Jones\u00a0RB, Specks\u00a0U, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79(9):1243\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2262_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles\u00a0P, Perrodeau \u00c9, Samson\u00a0M, et al. Long-term Rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated Vasculitis. Ann Intern Med. 2020;173(3):179\u201387.","journal-title":"Ann Intern Med"},{"issue":"8","key":"2262_CR56","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles\u00a0P, Terrier\u00a0B, Perrodeau \u00c9, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a\u00a0multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2262_CR57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","volume":"51","author":"G Tomasson","year":"2012","unstructured":"Tomasson\u00a0G, Grayson\u00a0PC, Mahr\u00a0AD, et al. Value of ANCA measurements during remission to predict a\u00a0relapse of ANCA-associated vasculitis\u2014a meta-analysis. Rheumatology (Oxford). 2012;51(1):100\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2262_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","volume":"18","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura\u00a0M, Specks\u00a0U, Tehranian\u00a0S, et al. Maintenance of remission and risk of relapse in myeloperoxidase positive antineutrophil cytoplasmic antibody-associated Vasculitis with kidney involvement. Clin J Am Soc Nephrol. 2023;18(1):47\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2262_CR59","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","volume":"31","author":"JS Sanders","year":"2016","unstructured":"Sanders\u00a0JS, de Joode\u00a0AA, DeSevaux\u00a0RG, et al. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase\u20113 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a\u00a0randomized clinical trial. Nephrol Dial Transplant. 2016;31(9):1453\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2262_CR60","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras\u00a0A, Pagnoux\u00a0C, Haubitz\u00a0M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"2262_CR61","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra\u00a0TF, Walsh\u00a0M, Mahr\u00a0A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0randomized controlled trial. JAMA. 2010;304(21):2381\u20138.","journal-title":"JAMA"},{"issue":"3","key":"2262_CR62","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.13417","volume":"291","author":"S Thietart","year":"2022","unstructured":"Thietart\u00a0S, Beinse\u00a0G, Smets\u00a0P, et al. Patients of 75\u00a0years and over with ANCA-associated vasculitis have a\u00a0lower relapse risk than younger patients: A\u00a0multicentre cohort study. J\u00a0Intern Med. 2022;291(3):350\u201363.","journal-title":"J Intern Med"},{"issue":"1","key":"2262_CR63","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13075-020-02341-6","volume":"22","author":"KE Sada","year":"2020","unstructured":"Sada\u00a0KE, Ohashi\u00a0K, Asano\u00a0Y, et al. Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies. Arthritis Res Ther. 2020;22(1):236.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2262_CR64","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/rheumatology\/kez589","volume":"59","author":"ZS Wallace","year":"2020","unstructured":"Wallace\u00a0ZS, Fu\u00a0X, Harkness\u00a0T, et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology (Oxford). 2020;59(9):2308\u201315.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2262_CR65","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","volume":"45","author":"A Kronbichler","year":"2015","unstructured":"Kronbichler\u00a0A, Jayne\u00a0DR, Mayer\u00a0G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45(3):346\u201368.","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"2262_CR66","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler\u00a0A, Kerschbaum\u00a0J, Gopaluni\u00a0S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2262_CR67","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","volume":"20","author":"D Chanouzas","year":"2019","unstructured":"Chanouzas\u00a0D, McGregor\u00a0JAG, Nightingale\u00a0P, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a\u00a0multi-center retrospective cohort study. BMC Nephrol. 2019;20(1):58.","journal-title":"BMC Nephrol"},{"key":"2262_CR68","doi-asserted-by":"publisher","first-page":"760708","DOI":"10.3389\/fimmu.2021.760708","volume":"12","author":"B Odler","year":"2021","unstructured":"Odler\u00a0B, Windpessl\u00a0M, Krall\u00a0M, et\u00a0al. The risk of severe infections following Rituximab administration in patients with autoimmune kidney diseases: Austrian ABCDE registry analysis. Front Immunol. 2021;12:760708.","journal-title":"Front Immunol"},{"issue":"1","key":"2262_CR69","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman\u00a0CA, Tervaert\u00a0JW, de Jong\u00a0PE, et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N\u00a0Engl J Med. 1996;335(1):16\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"2262_CR70","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0002-9343(90)90337-D","volume":"89","author":"BC Fox","year":"1990","unstructured":"Fox\u00a0BC, Sollinger\u00a0HW, Belzer\u00a0FO, et al. A\u00a0prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89(3):255\u201374.","journal-title":"Am J Med"},{"issue":"9","key":"2262_CR71","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1507476","volume":"374","author":"DA Talan","year":"2016","unstructured":"Talan\u00a0DA, Mower\u00a0WR, Krishnadasan\u00a0A, et al. Trimethoprim-Sulfamethoxazole versus placebo for uncomplicated skin abscess. N\u00a0Engl J Med. 2016;374(9):823\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"2262_CR72","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park\u00a0JW, Curtis\u00a0JR, Moon\u00a0J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2262_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis\u00a0GE, Nikiphorou\u00a0E, Dey\u00a0M, et\u00a0al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2022; https:\/\/doi.org\/10.1136\/ard-2022-223335.","journal-title":"Ann Rheum Dis"},{"key":"2262_CR74","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/tid.12651","volume":"19","author":"PE Messiaen","year":"2017","unstructured":"Messiaen\u00a0PE, Cuyx\u00a0S, Dejagere\u00a0T, et al. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A\u00a0systematic review. Transpl Infect Dis. 2017;19:2.","journal-title":"Transpl Infect Dis"},{"key":"2262_CR75","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts\u00a0DM, Jones\u00a0RB, Smith\u00a0RM, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J\u00a0Autoimmun. 2015;57:60\u20135.","journal-title":"J Autoimmun"},{"issue":"10","key":"2262_CR76","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","volume":"53","author":"E Besada","year":"2014","unstructured":"Besada\u00a0E, Koldingsnes\u00a0W, Nossent\u00a0JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2014;53(10):1818\u201324.","journal-title":"Rheumatology (Oxford)"},{"key":"2262_CR77","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12891-015-0860-3","volume":"17","author":"E Besada","year":"2016","unstructured":"Besada\u00a0E. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab. BMC Musculoskelet Disord. 2016;17:6.","journal-title":"BMC Musculoskelet Disord"},{"key":"2262_CR78","doi-asserted-by":"publisher","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","volume":"12","author":"J Tieu","year":"2021","unstructured":"Tieu\u00a0J, Smith\u00a0RM, Gopaluni\u00a0S, et\u00a0al. Rituximab associated Hypogammaglobulinemia in autoimmune disease. Front Immunol. 2021;12:671503.","journal-title":"Front Immunol"},{"issue":"5","key":"2262_CR79","doi-asserted-by":"publisher","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"N Venhoff","year":"2012","unstructured":"Venhoff\u00a0N, Effelsberg\u00a0NM, Salzer\u00a0U, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE. 2012;7(5):e37626.","journal-title":"PLoS ONE"},{"issue":"2","key":"2262_CR80","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","volume":"48","author":"G Boleto","year":"2018","unstructured":"Boleto\u00a0G, Avouac\u00a0J, Wipff\u00a0J, et al. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A\u00a012-year longitudinal multi-center study. Semin Arthritis Rheum. 2018;48(2):149\u201354.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"2262_CR81","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/ckj\/sfx014","volume":"10","author":"S Shah","year":"2017","unstructured":"Shah\u00a0S, Jaggi\u00a0K, Greenberg\u00a0K, et al. Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Kidney\u00a0J. 2017;10(4):470\u20134.","journal-title":"Clin Kidney J"},{"key":"2262_CR82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts\u00a0DM, Jones\u00a0RB, Smith\u00a0RM, et al. Immunoglobulin\u00a0G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a\u00a0case series. J\u00a0Autoimmun. 2015;57:24\u20139.","journal-title":"J Autoimmun"},{"issue":"4","key":"2262_CR83","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","volume":"59","author":"J Tieu","year":"2020","unstructured":"Tieu\u00a0J, Smith\u00a0R, Basu\u00a0N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford). 2020;59(4):e24\u2013e32.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2262_CR84","doi-asserted-by":"publisher","first-page":"104031","DOI":"10.1016\/j.lpm.2020.104031","volume":"49","author":"B Terrier","year":"2020","unstructured":"Terrier\u00a0B, Charles\u00a0P, Auma\u00eetre\u00a0O, et al. ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. Presse Med. 2020;49(3):104031.","journal-title":"Presse Med"},{"issue":"5","key":"2262_CR85","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/rheumatology\/key394","volume":"58","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka\u00a0S, Jayne\u00a0DR, Mukhtyar\u00a0C, et\u00a0al. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford). 2019;58(5):889\u201396.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2262_CR86","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3109\/03009742.2016.1138318","volume":"45","author":"A Knight","year":"2016","unstructured":"Knight\u00a0A, Sundstr\u00f6m\u00a0Y, B\u00f6rjesson\u00a0O, et al. Late-onset neutropenia after rituximab in ANCA-associated vasculitis. Scand J Rheumatol. 2016;45(5):404\u20137.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"2262_CR87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.41501","volume":"73","author":"R Zonozi","year":"2021","unstructured":"Zonozi\u00a0R, Wallace\u00a0ZS, Laliberte\u00a0K, et al. Incidence, clinical features, and outcomes of late-onset Neutropenia from Rituximab for autoimmune disease. Arthritis Rheumatol. 2021;73(2):347\u201354.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2262_CR88","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2215\/CJN.07300712","volume":"8","author":"R Goupil","year":"2013","unstructured":"Goupil\u00a0R, Brachemi\u00a0S, Nadeau-Fredette\u00a0AC, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2013;8(3):416\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2262_CR89","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/ard.54.12.991","volume":"54","author":"B Godeau","year":"1995","unstructured":"Godeau\u00a0B, Mainardi\u00a0JL, Roudot-Thoraval\u00a0F, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener\u2019s granulomatosis. Ann Rheum Dis. 1995;54(12):991\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"2262_CR90","doi-asserted-by":"publisher","first-page":"e843","DOI":"10.1097\/MD.0000000000000843","volume":"94","author":"YY Shi","year":"2015","unstructured":"Shi\u00a0YY, Li\u00a0ZY, Zhao\u00a0MH, et al. The CD4 lymphocyte count is a\u00a0better predictor of overall infection than the total lymphocyte count in ANCA-associated Vasculitis under a\u00a0Corticosteroid and Cyclophosphamide regimen: a\u00a0retrospective cohort. Medicine (Baltimore). 2015;94(18):e843.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2262_CR91","doi-asserted-by":"publisher","first-page":"101369","DOI":"10.1016\/j.beem.2019.101369","volume":"33","author":"J Khizroeva","year":"2019","unstructured":"Khizroeva\u00a0J, Nalli\u00a0C, Bitsadze\u00a0V, et\u00a0al. Infertility in women with systemic autoimmune diseases. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101369.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2262_CR92","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-3-319-69535-8_12","volume":"1034","author":"EZ Drobnis","year":"2017","unstructured":"Drobnis\u00a0EZ, Nangia\u00a0AK. Immunosuppressants and male reproduction. Adv Exp Med Biol. 2017;1034:179\u2013210.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"2262_CR93","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ncprheum0770","volume":"4","author":"MA Dooley","year":"2008","unstructured":"Dooley\u00a0MA, Nair\u00a0R. Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat Clin Pract Rheumatol. 2008;4(5):250\u20137.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"9","key":"2262_CR94","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrneph.2012.107","volume":"8","author":"N Wall","year":"2012","unstructured":"Wall\u00a0N, Harper\u00a0L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol. 2012;8(9):523\u201332.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2262_CR95","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/1744666X.2020.1724091","volume":"16","author":"SN Luong","year":"2020","unstructured":"Luong\u00a0SN, Isaacs\u00a0A, Liu\u00a0Z, et al. A\u00a0systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease. Expert Rev Clin Immunol. 2020;16(3):321\u201333.","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 3","key":"2262_CR96","doi-asserted-by":"publisher","first-page":"iii74","DOI":"10.1093\/rheumatology\/kez618","volume":"59","author":"R Smith","year":"2020","unstructured":"Smith\u00a0R. Complications of therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59(Suppl 3):iii74\u2013iii8.","journal-title":"Rheumatology (Oxford)"},{"issue":"1\u20132","key":"2262_CR97","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","volume":"131","author":"A Puchner","year":"2019","unstructured":"Puchner\u00a0A, Gr\u00f6chenig\u00a0HP, Sautner\u00a0J, et\u00a0al. Immunosuppressives and biologics during pregnancy and lactation: A\u00a0consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr. 2019;131(1\u20132):29\u201344.","journal-title":"Wien Klin Wochenschr"},{"issue":"12","key":"2262_CR98","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1002\/art.39317","volume":"67","author":"C Rahmattulla","year":"2015","unstructured":"Rahmattulla\u00a0C, Berden\u00a0AE, Wakker\u00a0SC, et al. Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated Vasculitis diagnosed between 1991 and 2013. Arthritis Rheumatol. 2015;67(12):3270\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2262_CR99","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/ard.2010.145250","volume":"70","author":"C Heijl","year":"2011","unstructured":"Heijl\u00a0C, Harper\u00a0L, Flossmann\u00a0O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis. 2011;70(8):1415\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2262_CR100","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3899\/jrheum.181438","volume":"47","author":"C Heijl","year":"2020","unstructured":"Heijl\u00a0C, Westman\u00a0K, H\u00f6glund\u00a0P, et al. Malignancies in patients with antineutrophil cytoplasmic antibody-associated Vasculitis: a\u00a0population-based cohort study. J\u00a0Rheumatol. 2020;47(8):1229\u201337.","journal-title":"J Rheumatol"},{"issue":"4","key":"2262_CR101","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.semarthrit.2021.03.014","volume":"51","author":"ST Choi","year":"2021","unstructured":"Choi\u00a0ST, Ahn\u00a0SV, Lee\u00a0PH, et al. The cancer risk according to three subtypes of ANCA-associated vasculitis: A\u00a0propensity score-matched analysis of a\u00a0nationwide study. Semin Arthritis Rheum. 2021;51(4):692\u20139.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2262_CR102","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen\u00a0EE, Rizzo\u00a0R, Kronbichler\u00a0A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(6):1064\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2262_CR103","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/rheumatology\/kev196","volume":"54","author":"M Calatroni","year":"2015","unstructured":"Calatroni\u00a0M, Buzio\u00a0C, Vaglio\u00a0A. The evolving paradigm of cancer risk related to cyclophosphamide therapy in granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(8):1339\u201341.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2262_CR104","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3899\/jrheum.160885","volume":"44","author":"EE van Daalen","year":"2017","unstructured":"van Daalen\u00a0EE, Rahmattulla\u00a0C, Wolterbeek\u00a0R, et al. Incidence of malignancy prior to antineutrophil cytoplasmic antibody-associated Vasculitis compared to the general population. J\u00a0Rheumatol. 2017;44(3):314\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"2262_CR105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/acr.23587","volume":"71","author":"JA Tan","year":"2019","unstructured":"Tan\u00a0JA, Choi\u00a0HK, Xie\u00a0H, et al. All-cause and cause-specific mortality in patients with Granulomatosis with Polyangiitis: a\u00a0population-based study. Arthritis Care Res (Hoboken). 2019;71(1):155\u201363.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"2262_CR106","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","volume":"76","author":"JA Tan","year":"2017","unstructured":"Tan\u00a0JA, Dehghan\u00a0N, Chen\u00a0W, et al. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017;76(9):1566\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2262_CR107","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1093\/rheumatology\/keab071","volume":"60","author":"S Moiseev","year":"2021","unstructured":"Moiseev\u00a0S, Kronbichler\u00a0A, Makarov\u00a0E, et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a\u00a0multinational study. Rheumatology (Oxford). 2021;60(10):4654\u201361.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2262_CR108","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.mayocp.2018.02.010","volume":"93","author":"A Berti","year":"2018","unstructured":"Berti\u00a0A, Matteson\u00a0EL, Crowson\u00a0CS, et al. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated Vasculitis: a\u00a020-year population-based cohort study. Mayo Clin Proc. 2018;93(5):597\u2013606.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2262_CR109","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3899\/jrheum.130200","volume":"40","author":"M Hilhorst","year":"2013","unstructured":"Hilhorst\u00a0M, Winckers\u00a0K, Wilde\u00a0B, et\u00a0al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J\u00a0Rheumatol. 2013;40(12):2042\u20136.","journal-title":"J Rheumatol"},{"issue":"5","key":"2262_CR110","first-page":"704","volume":"56","author":"A Kronbichler","year":"2017","unstructured":"Kronbichler\u00a0A, Leierer\u00a0J, Leierer\u00a0G, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. Rheumatology (Oxford). 2017;56(5):704\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2262_CR111","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/art.41017","volume":"71","author":"A Kronbichler","year":"2019","unstructured":"Kronbichler\u00a0A, Leierer\u00a0J, Shin\u00a0JI, et al. Association of pulmonary hemorrhage, positive proteinase 3, and urinary red blood cell casts with venous thromboembolism in antineutrophil cytoplasmic antibody-associated Vasculitis. Arthritis Rheumatol. 2019;71(11):1888\u201393.","journal-title":"Arthritis Rheumatol"},{"issue":"Supplement_3","key":"2262_CR112","doi-asserted-by":"publisher","first-page":"iii79","DOI":"10.1093\/rheumatology\/kez617","volume":"59","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler\u00a0A, Leierer\u00a0J, Gauckler\u00a0P, et al. Comorbidities in ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59(Supplement_3):iii79\u2013iii83.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2262_CR113","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","volume":"74","author":"J Robson","year":"2015","unstructured":"Robson\u00a0J, Doll\u00a0H, Suppiah\u00a0R, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2262_CR114","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/art.41006","volume":"71","author":"ZS Wallace","year":"2019","unstructured":"Wallace\u00a0ZS, Fu\u00a0X, Liao\u00a0K, et al. Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody-associated Vasculitis. Arthritis Rheumatol. 2019;71(11):1879\u201387.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"2262_CR115","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/jcm10112299","volume":"10","author":"C Roubille","year":"2021","unstructured":"Roubille\u00a0C, Henriquez\u00a0S, Mercuzot\u00a0C, et al. Impact of cardiovascular risk factors on the occurrence of cardiovascular events in antineutrophil cytoplasmic antibody (ANCA)-associated Vasculitides. J\u00a0Clin Med. 2021;10(11):2299.","journal-title":"J Clin Med"},{"issue":"4","key":"2262_CR116","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/jep.12709","volume":"23","author":"CP Bramlage","year":"2017","unstructured":"Bramlage\u00a0CP, Kr\u00f6plin\u00a0J, Wallbach\u00a0M, et al. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J\u00a0Eval Clin Pract. 2017;23(4):747\u201354.","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"2262_CR117","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","volume":"29","author":"FLJ Visseren","year":"2022","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM, et\u00a0al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022;29(1):5\u2013115.","journal-title":"Eur J Prev Cardiol"},{"issue":"3S","key":"2262_CR118","first-page":"S1","volume":"99","author":"KDIGO","year":"2021","unstructured":"KDIGO. 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1\u2013S87.","journal-title":"Kidney Int"},{"issue":"5","key":"2262_CR119","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1136\/annrheumdis-2021-221474","volume":"81","author":"M S\u00e4emann","year":"2022","unstructured":"S\u00e4emann\u00a0M, Kronbichler\u00a0A. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT\u20112 inhibitors. Ann Rheum Dis. 2022;81(5):614\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2262_CR120","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong\u00a0P, McCloskey\u00a0EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437\u201347.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2262_CR121","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s198-002-8341-z","volume":"13","author":"MM Boomsma","year":"2002","unstructured":"Boomsma\u00a0MM, Stegeman\u00a0CA, Kramer\u00a0AB, et al. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a\u00a0cross-sectional study. Osteoporos Int. 2002;13(1):74\u201382.","journal-title":"Osteoporos Int"},{"issue":"8","key":"2262_CR122","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3899\/jrheum.151151","volume":"43","author":"M Englund","year":"2016","unstructured":"Englund\u00a0M, Merkel\u00a0PA, Tomasson\u00a0G, et al. Comorbidities in patients with antineutrophil cytoplasmic antibody-associated Vasculitis versus the general population. J\u00a0Rheumatol. 2016;43(8):1553\u20138.","journal-title":"J Rheumatol"},{"issue":"2","key":"2262_CR123","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.autrev.2013.10.001","volume":"13","author":"M Samson","year":"2014","unstructured":"Samson\u00a0M, Pu\u00e9chal\u00a0X, Devilliers\u00a0H, et al. Long-term follow-up of a\u00a0randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev. 2014;13(2):197\u2013205.","journal-title":"Autoimmun Rev"},{"key":"2262_CR124","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0123-2021","author":"S Kadura","year":"2021","unstructured":"Kadura S, Raghu G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a\u00a0review. Eur Respir Rev. 2021. https:\/\/doi.org\/10.1183\/16000617.0123-2021.","journal-title":"Eur Respir Rev"},{"issue":"Suppl 4","key":"2262_CR125","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00508-016-1033-6","volume":"128","author":"U Wiedermann","year":"2016","unstructured":"Wiedermann\u00a0U, Sitte\u00a0HH, Burgmann\u00a0H, et\u00a0al. Guidelines for vaccination of immunocompromised individuals. Wien Klin Wochenschr. 2016;128(Suppl 4):337\u201376.","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"2262_CR126","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jbspin.2016.09.019","volume":"84","author":"M Groh","year":"2017","unstructured":"Groh\u00a0M, Pu\u00e9chal\u00a0X, Terrier\u00a0B, et al. Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1\u00a0study. Joint Bone Spine. 2017;84(5):643\u20134.","journal-title":"Joint Bone Spine"},{"issue":"10","key":"2262_CR127","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","volume":"80","author":"D Mrak","year":"2021","unstructured":"Mrak\u00a0D, Tobudic\u00a0S, Koblischke\u00a0M, et al. SARS-CoV\u20112 vaccination in rituximab-treated patients: B\u00a0cells promote humoral immune responses in the presence of T\u2011cell-mediated immunity. Ann Rheum Dis. 2021;80(10):1345\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2262_CR128","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","volume":"80","author":"M Prendecki","year":"2021","unstructured":"Prendecki\u00a0M, Clarke\u00a0C, Edwards\u00a0H, et al. Humoral and T\u2011cell responses to SARS-CoV\u20112 vaccination in patients receiving immunosuppression. Ann Rheum Dis. 2021;80(10):1322\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2262_CR129","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.kint.2021.09.002","volume":"100","author":"NL Li","year":"2021","unstructured":"Li\u00a0NL, Coates\u00a0PT, Rovin\u00a0BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int. 2021;100(5):959\u201365.","journal-title":"Kidney Int"},{"issue":"2","key":"2262_CR130","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.kint.2021.11.013","volume":"101","author":"A Kronbichler","year":"2022","unstructured":"Kronbichler\u00a0A, Jung\u00a0SY, Kim\u00a0MS, et al. Distinct glomerular disease association after vaccination with BNT162b2 and mRNA-1273: a\u00a0VigiBase analysis. Kidney Int. 2022;101(2):415\u20136.","journal-title":"Kidney Int"},{"issue":"6","key":"2262_CR131","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.kint.2022.08.021","volume":"102","author":"M Diebold","year":"2022","unstructured":"Diebold\u00a0M, Locher\u00a0E, Boide\u00a0P, et al. Incidence of new onset glomerulonephritis after SARS-CoV\u20112 mRNA vaccination is not increased. Kidney Int. 2022;102(6):1409\u201319.","journal-title":"Kidney Int"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02262-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:18:03Z","timestamp":1695201483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02262-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":131,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02262-9","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"24 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.\u00a0Odler, M.\u00a0Windpessl, K.\u00a0Eller, M.D.\u00a0S\u00e4emann, K.\u00a0Lhotta, I.\u00a0Neumann, G.\u00a0\u00d6berseder, C.\u00a0Duftner, C.\u00a0Dejaco, M.\u00a0Rudnicki, P.\u00a0Gauckler, R.\u00a0Hintenberger, J.\u00a0Zwerina, J.\u00a0Thiel und A.\u00a0Kronbichler geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}